The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.
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The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.
T umors in mice and humans often contain infiltrates of immune cells. Experiments with immune-deficient mice have provided data supporting the role of adaptive immunity in cancer immunosurveillance (1) (2) (3) (4) . Tumor cells can express antigens and become targets for a T cell-mediated adaptive immune response (5, 6) . The differentiation of naBve CD4 þ T cells into T helper type 1 (T H 1) cells producing interferon gamma (IFN-g) promotes CD8 T cell-mediated adaptive immunity (7 ) . In mice, immune cells appear to prevent the development of tumors and inhibit tumor progression (1, 3, 4) . Anti-tumor immunity also leads to immunoediting, a process favoring the eventual outgrowth of tumor cells with reduced immunogenicity (3).
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The role of immune cells in human neoplasia is less clear (8) . Immune cells can release inflammatory mediators with proangiogenic and prometastatic effects (9) (10) (11) (12) (13) (14) . Tumor-infiltrating lymphocytes in melanoma (15) , colorectal cancers (CRCs) (16) (17) (18) , and ovarian cancers (19, 20) have been shown to inhibit tumor growth and are associated with improved prognoses. After antigen stimulation, a small population of antigen-specific memory T cells remains in the tissues (21) . We recently showed that human CRCs with a high density of infiltrating memory and effector memory T cells were less likely to disseminate to lymphovascular and perineural structures and to regional lymph nodes (22) . Using the same cohort of patients, we investigated the relationship between the type, density, and location of immune cells within tumors and the clinical outcome of the patients.
To this end, we conducted genomic and in situ immunostaining analyses on tumors from 75 and 415 patients, respectively (table S1). The data were entered into a dedicated Tumoral MicroEnvironment Database (TME.db; access available upon request). We used quantitative real-time polymerase chain reaction to evaluate the expression levels of genes related to inflammation, T H 1 adaptive immunity, and immunosuppression. These genes showed variable expression patterns in the 75 tumors studied ( fig. S1 ). Correlation analyses performed between all genes showed 39 highly significant combinations (P G 0.0001) (fig. S1 and table S2). We identified a dominant cluster of comodulated genes for T H 1 adaptive immunity Egenes encoding T-box transcription factor 21, interferon regulatory factor 1, IFN-g, CD3-z, CD8, granulysin, and granzyme B (GZMB) (  Fig. 1A) . A hierarchical tree structure classifying the patients according to the expression levels of genes from this cluster revealed an inverse correlation between the expression of these genes and tumor recurrence (P value comparing patient groups, all P G 0.05) (Fig.  1B) . These data suggest that T H 1 adaptive immunity has a beneficial effect on clinical outcome.
We next used tissue microarrays to investigate the in situ adaptive immune response in the center of the tumor (CT) and the invasive margin (IM) of 415 CRCs. Immunostainings for total T lymphocytes (CD3), CD8 T cell effectors and their associated cytotoxic molecule (GZMB), and memory T cells (CD45RO) were quantified with the use of a dedicated image analysis workstation ( Fig. 2A and figs. S2 to S4). Tumors from patients without recurrence had higher immune cell densities (CD3, CD8, GZMB, and CD45RO) within each tumor region (CT and IM), than did those from patients whose tumors had recurred (Fig. 2B) . In each tumor region (CT and IM) and for each marker (CD3, CD8, GZMB, and CD45RO), there was a statistically significant correlation between immune cell density and patient outcome for a large range of cutoff values ( fig. S5 ). In particular, using the cutoff that yielded the minimum P value for disease-free survival, the densities of CD3 þ , CD8 þ , GZMB þ , and CD45RO þ cells in each tumor region (CT and IM) allowed the stratification of patients into groups with different disease-free survival rates EP values corrected after (23) , ranging from 1.0 Â 10 j2 to 4.8 Â 10 j6^a nd overall survival rates (P values ranging from 5.5 Â 10 j3 to 7.9 Â 10 j8 ) (Fig.  2C and tables S3 and S4) . Reanalyses of the data using 100 repetitions of twofold crossvalidations after (24) (tables S3 and S4) or setting the cutoff at the median of the data sets (tables S5 and S6) provided concordant results as to the prognostic value of each immune parameter.
We investigated whether the combined analysis of tumor regions could improve the prediction of patient survival. For all the markers of adaptive immunity (CD3, CD8, GZMB, and CD45RO), the combined analysis of CT plus IM regions Ehigh density in both regions (HiHi) versus low density in both regions (LoLo)î ncreased the accuracy of prediction of diseasefree and overall survival time for the different patient groups, as compared to single-region analysis (Hi versus Lo) (Fig. 2, D to F; figs. S6 and S7; and tables S3 to S6). Data were also analyzed using twofold cross-validation after (table S1 ). The correlation matrix reveals a dominant cluster of co-modulated genes for T H 1 adaptive immunity and two clusters of genes encoding mediators of inflammation and immunosuppression. (B) Hierarchical tree structure classifying the 75 patients according to the mRNA levels of the seven genes from the T H 1 adaptive cluster, from maximal (red) to minimal (blue) expression levels. The percentage of patients with tumor recurrence (relapse) is indicated. Patients with a homogeneous increased expression of genes for T H 1 adaptive immunity had the best prognosis. Log-rank tests comparing the disease-free survival times between patient groups reached statistical significance (P G 0.05 for numbers 1, 2, and 3). In contrast, expression levels of inflammatory and immunosuppressive genes showed no correlation with tumor recurrence. MMP-7, matrix metalloproteinase 7; PTSG2, prostaglandin-endoperoxide synthase 2; IL8, interleukin-8; BIRC5, baculoviral IAP repeat-containing 5 (survivin); CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1; GLNY, granulysin; IRF1, interferon regulatory factor 1; TBX, T-box 21 (TBET); TNFRSF10A, tumor necrosis factor receptor superfamily, member 10a (TRAILR1); TGFB1, transforming growth factor-b 1; VEGF, vascular endothelial growth factor. 1961 REPORTS (24) (100 repetitions for each marker), showing highly significant differences (tables S3 and S4). CD3 CT /CD3 IM density was associated with the smallest P values for disease-free and overall survival analyses (P 0 7.6 Â 10 j8 and P 0 4.0 Â 10 j7 , respectively) (tables S3 and S4). To confirm these results, we analyzed an additional cohort of patients who were different from those in the first series and a third cohort of CRC patients from another hospital. For each cohort, we determined the median cutoff values for CD3 CT /CD3 IM density (50% of patients with a high density and 50% of patients with a low density). The two independent cohorts (Fig. 2, E and F) confirmed the data obtained on the first series (Fig. 2D) . All statistical analyses were also performed for the subgroup of patients without concomitant distant metastasis EUnion Internationale Centre le Cancer-Tumor Node Metastasis (UICC-TNM) cancer stages I, II, and III^. Significant P values were observed for CD3 CT /CD3 IM , CD8 CT /CD8 IM , and CD45RO CT /CD45RO IM densities for predicting disease-free survival and overall survival (figs. S8 and S9 and tables S7 to S10).
We determined whether these immune criteria could discriminate patient outcome at each step of cancer progression. Patients were stratified according to the UICC-TNM classification (25) (Fig. 3A) . A strong in situ immune reaction in both tumor regions correlated with a favorable prognosis regardless of the local extent of the tumor and of invasion of regional lymph nodes (stages I, II, and III). Conversely, a weak in situ immune reaction in both tumor regions correlated with a poor prognosis even in patients with minimal tumor invasion (stage I) (Fig. 3B) . We recently demonstrated the importance of the density of CD45RO þ memory T cells in limiting the tumor dissemination of CRCs (22) . We found that patients with low densities of CD3 þ cells and CD45RO þ memory T cells in both tumor regions (CT and IM) had a very poor prognosis, similar to that of patients with concomitant distant metastasis Kaplan-Meier curves illustrate the duration of disease-free survival according to the CD3 þ cell density in a single tumor region in the CT (left panels) or IM (middle panels) and in both tumor regions (right panels). In each cohort, for each tumor region, high (Hi) and low (Lo) CD3 densities were plotted according to the cutoff value of CD3 þ cell density defined at the median of the cohort (50% of patients with high cell density and 50% of patients with low cell density (Fig. 3C) . In multivariate analysis, after adjusting for tumor invasion (T stage), tumor differentiation, and lymph node invasion (N stage), CD3 CT /CD3 IM density (HiHi, Heterogeneous, and LoLo) remained an independent prognostic factor, with the highest hazard ratio (HR) and the smallest P value in disease-free survival analysis EHR 0 2.379; P 0 1.4 Â 10 j6 , corrected after (26)^(table S11). CD3 CT /CD3 IM density was the only independent parameter associated with overall survival (HR 0 1.89; P 0 1.2 Â 10 j5 ) (table S12). The histopathological parameters were no longer associated with disease-free and overall survival in patients with coordinated high or low densities of the immune markers in both tumor regions (HiHi versus LoLo) (tables S11 and S12). Our results suggest that once human CRCs become clinically detectable, the adaptive immune response plays a role in preventing tumor recurrence. Despite immunoediting (2), the beneficial effect of the adaptive immunity may persist throughout tumor progression (stages II and III). Intratumoral T cells could modify tumor stroma or tumor cells in ways that attenuate the metastatic potential of tumor cells. We found a positive correlation between the presence of markers for T H 1 polarization and of cytotoxic and memory T cells and a low incidence of tumor recurrence. This argues for immune-mediated rejection of persistent tumor cells after surgery. We hypothesize that the trafficking properties and long-lasting anti-tumor capacity of memory T cells (27) play a central role in the control of tumor recurrence.
The type, density, and location of immune cells in CRCs had a prognostic value that was superior to and independent of those of the UICC-TNM classification (25) . This suggests that time to recurrence and overall survival time are governed in large part by the state of the local adaptive immune response. The immunological criteria that we have used may lead to revision of the current indicators of clinical outcome and may help identify the high-risk patients who would benefit most from adjuvant therapy. Finally, this approach may be useful for the investigation of other tumor types. 
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Patients and database
The records of 415 colorectal cancer (CRC) patients who underwent a primary resection of their tumor at the Laennec-HEGP Hospitals between 1990 and 2003 were reviewed. These 415 patients from Laennec-HEGP Hospitals were the main subject of our study (Table S1) , and have been previously described (22) .
Paraffin-embedded tumor samples were available from 150 consecutive ribosomal RNA primers and probe were used as internal control. Data were analyzed using the SDS Software v2.2 (Applied-Biosystems).
List of genes analyzed by Low Density Arrays: (adaptive immune response, T H1 polarization, inflammation, immunosuppression, and tumor-related genes). Tissue-cores arrayed into recipient paraffin-blocks were cut into 5 µm sections for
Harris's hematoxylin (HE) and immunohistochemical staining.
Immunohistochemistry
Tissue microarray sections were incubated (60 min. at room temperature) with monoclonal antibodies against CD3 (SP7), CD8 (4B11), CD45RO (OPD4), GZMB (GrB-7), cytokeratin (AE1AE3) and cytokeratin-8 (Neomarkers, Fremont, CA).
Envision+ system (enzyme-conjugated polymer backbone coupled to secondary antibodies) and DAB-chromogen were applied (Dako, Copenhagen, Denmark). 
Statistical analysis
Genesis clustering software (28) was used to visualize the correlation matrix presented in Figure 1 and to perform Pearson un-centered hierarchical clustering.
The pvcluster R package was used to validate the found clusters. respectively. Because the P-values obtained in this way might present severe overfitting, DFS log-rank P-values were corrected using the formula proposed by Altman et al (23) . Additionally, DFS and OS log-rank P-values were calculated using 2-fold cross-validation after (24) . 100 repetitions were performed (with and without stratifying on the grouping variable). The median p-values are summarized in Tables   S4-S5 and S7-S8. A multivariate Cox proportional hazards model was applied to the CD3 CT CD3 IM combined regions marker to determine its hazard ratio after adjustment by traditional histopathological tumor markers. The Cox model was applied only to patients with UICC-TNM, I, II, III to guarantee a common baseline hazard function. Hazard ratios from the DFS model were corrected using a shrinkage factor estimated from leaveone-out cross-validation as suggested by Holländer et al (26) . Models using the median as cutoff are presented in the Supplementary Tables. Additionally, the markers of interest were an independent prognostic factor when considering the markers of interest in its original continuous scale (data not shown).
All through the text a P-value < 0.05 was considered statistically significant. All analyses were performed with the statistical software R (survival package) and Statview. No. of Patients Cohorts † The stage was determined by pathological (p) examination. T1 tumor invading submucosa, T2 tumor invading muscularis propria, T3 tumor penetrating muscularis propria and invading subserosa, and T4 tumor invading other organs or structures or perforating visceral peritoneum. ‡ It was not possible to determine the nodal status of two patients. 
